BLU:NSD-BELLUS Health Inc

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.10

Change

-0.14 (-1.93)%

Market Cap

USD 0.39B

Volume

0.13M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Employees : 10

Currency: USD

Country : USA

Market Stats

Beta : 1.37

52 Week High : 7.88

52 Week Low : 0.05

50 Day Moving Average : 7.27

200 Day Moving Average : 5.67

Shorted Shares : 4,912

Shorted Shares Previous Month : 10,403

Short Ratio : 11.98

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-09-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+2.61 (+1.49%)

 USD 44.97B 20.53 41.60
REGN Regeneron Pharmaceuticals, Inc

+4.27 (+1.52%)

 USD 30.93B 15.64 12.43
ALXN Alexion Pharmaceuticals, Inc

+1.14 (+1.06%)

 USD 24.08B 18.20 10.98
INCY Incyte Corporation

+1.91 (+2.50%)

 USD 16.44B 53.79 40.58
BMRN BioMarin Pharmaceutical Inc

+1.56 (+2.15%)

 USD 13.04B N/A -203.31
GMAB Genmab A/S

+0.04 (+0.20%)

 USD 12.96B N/A -0.00
SGEN Seattle Genetics, Inc

+0.48 (+0.68%)

 USD 11.42B N/A -54.28
GLPG Galapagos NV

-2.76 (-1.71%)

 USD 9.94B 72.40 0.00
ALNY Alnylam Pharmaceuticals, Inc

+1.08 (+1.29%)

 USD 9.31B N/A -8.80
IONS Ionis Pharmaceuticals, Inc

-1.07 (-1.62%)

 USD 9.30B 23.32 72.05

ETFs Containing BLU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.39B 64% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -38.36 91% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.81% 57% F 20% F
Return on Invested Capital -25.77% 73% C 24% F
Return on Assets -32.86% 42% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.98 24% F 14% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.37 57% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.